Cervix News and Research

RSS

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% vaginal progesterone gel to reduce the risk of preterm birth in women with a short cervical length as measured by transvaginal ultrasound at mid-pregnancy.

7 Dec 2010

APP to launch Topotecan for Injection following FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Topotecan for Injection, and plans to launch immediately.

30 Nov 2010

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

24 Nov 2010

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

22 Nov 2010

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

In a study published today in the International Journal of Cancer, Gen-Probe's APTIMA HPV Assay provided a better combination of sensitivity and specificity than HPV DNA- or cytology-based tests for cervical cancer screening.

18 Nov 2010

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

The Bill & Melinda Gates Foundation has awarded nationally prominent Oregon Health & Science University reproductive scientist Jeffrey T. Jensen, M.D., M.P.H., a $100,000 grant to investigate the safety and effectiveness of a novel low-cost family-planning option that may be applicable to women in low-resource countries worldwide.

15 Nov 2010

Forceps delivery can pose risk to mother and child

Forceps might be a better instrument than a vacuum cup for assisting a successful birth, but new mothers might experience more trauma and complications after a forceps delivery, according to a new review of studies.

10 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Novel serum test may help diagnose early pregnancy location and outcome

Researchers may have identified a promising novel diagnostic biomarker for ectopic pregnancy, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). In the western world, deaths from ectopic pregnancy are not common but in the developing world one in ten women who are admitted with an ectopic pregnancy die.

4 Nov 2010

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.

1 Nov 2010

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

A study of the options for reducing cancer incidence and mortality among women who have been treated for precancerous cervical lesions found that an annual conventional Pap smear is a cost effective strategy.

21 Oct 2010

National Pap Test Campaign for cervical cancer diagnosis

The Federation of Medical Women of Canada (FMWC) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) are ready to launch this year's National Pap Test Campaign, to take place during National Cervical Cancer Awareness Week. From October 24th to 30th, over 100 health-care professionals across Canada are taking a stand against cervical cancer by hosting public Pap test clinics in their community.

20 Oct 2010

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.

12 Oct 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Smoking leads to epigenetic changes associated with cancer development: Research

For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer.The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

DCGI approves ADXS11-001 human testing for cervix cancer

As part of approving the human testing of ADXS11-001 the lead agent for the treatment of cervix cancer of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use.

23 Sep 2010

Cook Medical invites experts to discuss postpartum hemorrhage

Cook Medical has invited experts in women's health and postpartum hemorrhage from North America, Europe, Middle East and Africa to participate in a roundtable discussion with the world press to explore the causes, risk factors and prevalence of postpartum hemorrhage (PPH) a fatal complication of childbirth that affects approximately 14 million women annually.

21 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Three quarters of British adults support removal of shop displays of tobacco: Survey

Three quarters of British adults support the removal of shop displays of tobacco (73 per cent) and a complete ban on cigarette vending machines (77 per cent) according to a new survey commissioned by Cancer Research UK this weekend.

10 Sep 2010

Wealthy patients beat cancer better than poorer counterparts: Survey

Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.

10 Sep 2010

Cervix News and Research

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

APP to launch Topotecan for Injection following FDA marketing approval

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

Forceps delivery can pose risk to mother and child

People with SLE more likely to develop hematologic malignancies

Novel serum test may help diagnose early pregnancy location and outcome

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

National Pap Test Campaign for cervical cancer diagnosis

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Smoking leads to epigenetic changes associated with cancer development: Research

DCGI approves ADXS11-001 human testing for cervix cancer

Cook Medical invites experts to discuss postpartum hemorrhage

Nucletron to present innovative cancer treatment during ESTRO29

Three quarters of British adults support removal of shop displays of tobacco: Survey

Wealthy patients beat cancer better than poorer counterparts: Survey

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News